Inhibiting MD2 activates AMPK-dependent PPARγ/NOX4 signaling to attenuate mitochondrial oxidative stress and relieve pulmonary hypertension
- 1Pulmonary Division, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Interdisciplinary and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou, Zhejiang, 325035, China; Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China
- 2Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China
Abstract
Aims: Pulmonary hypertension (PH), a severe vascular disorder, is closely associated with chronic inflammatory states and oxidative stress. Myeloid differentiation protein 2 (MD2), a key co-receptor of Toll-like receptor 4 (TLR4), is well established in mediating various inflammation-driven pathologies. However, its role in pulmonary hypertension and its potential involvement in oxidative stress regulation remain unclear. Methods and results: MD2 expression was upregulated in both PH patients and murine PH models. Genetic or pharmacological inhibition of MD2 improved hemodynamic parameters, attenuated pulmonary vascular remodeling, and reduced right ventricular hypertrophy. MD2 inhibition significantly reduced mitochondrial oxidative stress in vivo and in vitro . Mechanistic studies demonstrated that suppression of the membrane protein MD2 activated intracellular AMP-activated protein kinase (AMPK) signaling, leading to enhanced peroxisome proliferator-activated receptor γ (PPARγ) activity. PPARγ, in turn, suppressed nuclear transcription of NADPH oxidase 4 (NOX4), resulting in a marked reduction in mitochondrial oxidative stress. Conclusion: This study indicates that MD2 may act as an upstream regulator of mitochondrial oxidative stress in PH. Inhibition of MD2 attenuates pulmonary hypertension through activation of the AMPK/PPARγ axis, which suppresses NOX4 mediated mitochondrial oxidative stress. Targeting MD2 may represent a novel therapeutic strategy for PH.
Related
- Mechanical compression activates cAMP signaling in Pseudomonas aeruginosa
- Covalent Targeting of the SKP1-βTrCP Interface Activates NRF1/2 Signaling
- Intranuclear localisation of KLF3‐AS1 under the balance of histone acetylation and methylation in BMSCs ameliorates cerebral ischaemia‒reperfusion injury by preserving microglial mitochondrial function and inhibiting inflammatory polarisation
- Pat1 globally activates deadenylation-dependent decapping to clear inefficiently translated oligo(A)-tailed transcripts
- Alistipes-derived monomethyl branched-chain fatty acid iso-15:0 suppresses hepatocellular carcinoma progression by inhibiting Gβγ/PI3K/AKT signaling.
BibTeX
@article{chen2026inhibiting,
title = {{Inhibiting MD2 activates AMPK-dependent PPARγ/NOX4 signaling to attenuate mitochondrial oxidative stress and relieve pulmonary hypertension}},
author = {Jun Chen and Mengyu Chai and Yichen Liu and Yaxin Zhang and Xiuchun Li and Congxuan Yang and Haofeng Pan and Chen Xu and Yizhu Yao and Yahan Yu and Juntao Chen and Dan Yao and Xiaoying Huang},
journal = {Redox Biology},
year = {2026},
month = oct,
doi = {10.1016/j.redox.2026.104454},
url = {https://doi.org/10.1016/j.redox.2026.104454},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Inhibiting MD2 activates AMPK-dependent PPARγ/NOX4 signaling to attenuate mitochondrial oxidative stress and relieve pulmonary hypertension
AU - Jun Chen
AU - Mengyu Chai
AU - Yichen Liu
AU - Yaxin Zhang
AU - Xiuchun Li
AU - Congxuan Yang
AU - Haofeng Pan
AU - Chen Xu
AU - Yizhu Yao
AU - Yahan Yu
AU - Juntao Chen
AU - Dan Yao
AU - Xiaoying Huang
PY - 2026
DA - 2026/10/23
JO - Redox Biology
DO - 10.1016/j.redox.2026.104454
UR - https://doi.org/10.1016/j.redox.2026.104454
AB - Aims: Pulmonary hypertension (PH), a severe vascular disorder, is closely associated with chronic inflammatory states and oxidative stress. Myeloid differentiation protein 2 (MD2), a key co-receptor of Toll-like receptor 4 (TLR4), is well established in mediating various inflammation-driven pathologies. However, its role in pulmonary hypertension and its potential involvement in oxidative stress regulation remain unclear. Methods and results: MD2 expression was upregulated in both PH patients and murine PH models. Genetic or pharmacological inhibition of MD2 improved hemodynamic parameters, attenuated pulmonary vascular remodeling, and reduced right ventricular hypertrophy. MD2 inhibition significantly reduced mitochondrial oxidative stress in vivo and in vitro . Mechanistic studies demonstrated that suppression of the membrane protein MD2 activated intracellular AMP-activated protein kinase (AMPK) signaling, leading to enhanced peroxisome proliferator-activated receptor γ (PPARγ) activity. PPARγ, in turn, suppressed nuclear transcription of NADPH oxidase 4 (NOX4), resulting in a marked reduction in mitochondrial oxidative stress. Conclusion: This study indicates that MD2 may act as an upstream regulator of mitochondrial oxidative stress in PH. Inhibition of MD2 attenuates pulmonary hypertension through activation of the AMPK/PPARγ axis, which suppresses NOX4 mediated mitochondrial oxidative stress. Targeting MD2 may represent a novel therapeutic strategy for PH.
SN - 2213-2317
ER -